EQT, IDG Capital Vie for Peptide Drug Maker PolyPeptide

The race to acquire PolyPeptide Group, a prominent Swiss contract drug manufacturer specializing in peptide-based therapeutics, has intensified as the field of potential buyers narrows. Sources indicate that private equity giants EQT AB and IDG Capital have advanced to the next stage of the auction process, signaling significant interest in the company's unique capabilities within the pharmaceutical supply chain.

While EQT and IDG Capital are the primary contenders moving forward, US-based Altaris also remains actively involved in the ongoing sale discussions. The process is still fluid, with no definitive agreements reached as bidders conduct thorough due diligence and scrutinize financial data in anticipation of formal offers. PolyPeptide, which commands a market valuation of approximately $1.6 billion following a recent upward trend in its share price, is nevertheless trading below its historical peaks from several years ago.

PolyPeptide, established in 1993, plays a crucial role in developing peptide APIs (Active Pharmaceutical Ingredients) essential for a wide array of treatments targeting metabolic disorders, oncology, cardiovascular diseases, and neurological conditions. The company boasts a global manufacturing footprint, with facilities strategically located across Europe, the United States, and India, enabling it to serve a diverse international clientele within the pharmaceutical sector. The company's ownership is currently held by billionaire Frederik Paulsen.

This potential transaction underscores the robust private equity appetite for healthcare assets within Switzerland and the broader European region. The pharmaceutical services sector, particularly contract development and manufacturing organizations (CDMOs) with specialized expertise like peptide synthesis, continues to attract substantial investment. The global peptide therapeutics market is projected to experience significant growth, driven by advancements in drug discovery and the increasing demand for complex biologics.

The strategic review initiated by PolyPeptide in April followed earlier indications of acquisition interest. At the time, the company cautioned that the exploration of strategic options did not guarantee a transaction would materialize. The current shortlist suggests a serious commitment to exploring a sale, with EQT and IDG Capital likely recognizing the company's strong market position and growth potential in a specialized niche.

EQT, known for its extensive investments across various sectors including healthcare and industrial carve-outs, and IDG Capital, with a portfolio spanning consumer and lifestyle brands, bring different but complementary investment philosophies. Their engagement highlights the competitive nature of acquiring high-value pharmaceutical manufacturing assets. Recent comparable deals, such as Lone Star Funds' acquisition of a Lonza Group unit and SK Capital Partners' investment in Swixx Biopharma, illustrate the ongoing consolidation and strategic repositioning within the pharmaceutical services industry.